ArticleJournal of advanced research2026
Tetramethylpyrazine improves the structure and function of mitochondrial-associated endoplasmic reticulum membrane and liver fibrosis.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrated transcriptomic and metabolomic profiling reveals immune-metabolic crosstalk and predictive biomarkers of ligustrazine treatment response in idiopathic pulmonary fibrosis.Journal of translational medicine · 2026Article
- Structural and Functional Alterations of MAMs and Their Immunomodulatory Roles in Sepsis-Induced Lung Injury.Journal of immunology research · 2026Review
- Tetramethylpyrazine exerts neuroprotective effects in a mouse model of acute hypobaric hypoxia.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMorphological and functional abnormalities of mitochondrial-associated endoplasmic reticulum (ER) membrane (MAM) have emerged as a key mediator of organelle dysfunction during liver fibrosis. Tetramethylpyrazine (TMP) was investigated as a potential therapy for liver fibrosis with an unclear mechanism.
objectivesConsidering the changes of MAM quantity and gap distance during liver fibrosis, we aimed to investigate the underlying mechanisms and their potential as therapeutic targets for TMP in inhibiting liver fibrosis.
methodsThrough different sequencing techniques and a series of molecular biology experiments, we explored the effects and mechanisms of TMP in CCl
resultsAn aberrant increase in the numbers of MAM and drastic alterations in the morphology of ER and mitochondria were accompanied by a substantial influx of Ca
conclusionHere, we highlight the therapeutic potential of TMP in liver fibrosis by elucidating its role in repairing hepatic MAM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.